Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07569744
NA

Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes

Sponsor: Universitas Sriwijaya

View on ClinicalTrials.gov

Summary

Type 2 diabetes mellitus is associated with endothelial dysfunction, which contributes to increased cardiovascular risk. Chronic hyperglycemia induces oxidative stress and reduces nitric oxide bioavailability, leading to impaired endothelial function. Resveratrol, a natural polyphenol with antioxidant and anti-inflammatory properties, has been shown to improve endothelial function in experimental studies. This randomized controlled trial aims to evaluate the effectiveness of resveratrol supplementation in improving endothelial dysfunction and metabolic control in patients with type 2 diabetes mellitus. Endothelial function will be assessed using flow-mediated dilatation (FMD) of the brachial artery and serum endothelial nitric oxide synthase (eNOS) levels. Metabolic parameters including fasting blood glucose, postprandial glucose, HbA1c, and lipid profile will also be evaluated.

Official title: Effectiveness of Resveratrol Addition in Improving Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-05

Completion Date

2026-10

Last Updated

2026-05-06

Healthy Volunteers

No

Interventions

DRUG

Resveratrol

Resveratrol 50 mg administered orally once daily for 12 weeks.

DRUG

Placebo

Matching placebo administered orally once daily for 12 weeks.

Locations (1)

Universitas Sriwijaya

Palembang, South Sumatera, Indonesia